{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"76.3","upperLimit":"85.7","value":"81.3"}]}],"title":"Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.8","upperLimit":"85.2","value":"80.8"}]}],"title":"Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.8","upperLimit":"84.4","value":"79.9"}]}],"title":"Central Reader 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"296"}],"units":"Participants"}],"description":"This analysis included patients in the EAP with rhPSMA-7.3 (18F) imaging where no LN metastases were detected and LN surgical pathology was available; where NPV=TN/(TN+FN).","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients who received rhPSMA-7.3 (18F) injection followed by a PET/CT scan and who underwent RP and PLND","id":"OG000","title":"Efficacy Analysis Population (EAP)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration","title":"NPV of rhPSMA-7.3 (18F) PET for Detecting PLN Metastases Compared to Surgical Pathology on a Patient-level, in Which a FN Patient is Defined as Having at Least One FN Region (Right or Left Pelvis), Regardless of Any Coexisting TN Findings (Objective 5)","type":"SECONDARY","unitOfMeasure":"percentage"}